[Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease]

Zhonghua Er Ke Za Zhi. 2006 May;44(5):329-32.
[Article in Chinese]

Abstract

Objective: The study was designed to investigate the changes in CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell in Kawasaki disease (KD).

Methods: The authors detected CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell by using flow cytometry. The patients who met the diagnostic criteria for KD comprised sixteen boys and fifteen girls (4 - 60 months of age; mean, 26 +/- 18 months). All received intravenous gammaglobulin at a dose of 1 g/(kg.d), for 2 days and oral aspirin at a dose of 30 - 50 mg/(kg.d). In case of persistent fever, a repeated dose of intravenous gammaglobulin or I.V. methylprednisolone at a dose of 20 mg/(kg.d) for three daily doses was attempted. The authors tested blood samples from 17 healthy controls consisting of nine boys and eight girls (3 - 84 months of age; mean, 25 +/- 18 months) and the samples from 31 patients.

Results: The percentage of peripheral blood CD(3)(+) T lymphocyte was (54.4 +/- 9.0)% in acute stage of KD and (65.0 +/- 7.0)% in healthy controls. There was a significant difference between the two groups (P < 0.001). The values of CD(69)(+) [(11.2 +/- 12.6)%, vs. (0.6 +/- 0.4)%], CD(25)(+) [(9.2 +/- 3.5)% vs. (3.9 +/- 1.8)%] and HLA-DR(+) [(8.3 +/- 5.0)% vs. (4.3 +/- 2.3)%] in KD patients were markedly increased compared to those of the healthy controls. After intravenous gammaglobulin treatment, the percentage of CD(3)(+)CD(69)(+) and CD(3)(+)CD(25)(+) significantly decreased [CD(3)(+)CD(69)(+): (14.0 +/- 13.0)% vs. (1.6 +/- 1.2)%, P < 0.05; CD(3)(+)CD(25)(+): (7.8 +/- 4.1)% vs. (2.0 +/- 0.6)%, P < 0.01]. However, the CD(3)(+) T lymphocytes increased [(50.8 +/- 5.0)% vs. (64.9 +/- 5.5)%, P < 0.01]. There was no significant difference in expression of CD(3)(+) T lymphocyte cell activating markers between coronary artery disease group and normal coronary artery group in KD cases (P > 0.05).

Conclusion: CD(3)(+) T cell activation in the early and middle stages is involved in the mechanism responsible for cardiovascular injury.

Publication types

  • English Abstract

MeSH terms

  • Antigens, CD / blood*
  • Antigens, Differentiation, T-Lymphocyte / blood*
  • Aspirin / administration & dosage
  • Aspirin / therapeutic use
  • Biomarkers / blood
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Flow Cytometry
  • Glucocorticoids / therapeutic use
  • HLA-DR Antigens / blood*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / therapeutic use
  • Infant
  • Interleukin-2 Receptor alpha Subunit / blood*
  • Lectins, C-Type / blood*
  • Male
  • Methylprednisolone / therapeutic use
  • Mucocutaneous Lymph Node Syndrome / blood
  • Mucocutaneous Lymph Node Syndrome / diagnosis
  • Mucocutaneous Lymph Node Syndrome / drug therapy
  • Mucocutaneous Lymph Node Syndrome / immunology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prognosis
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • Treatment Outcome

Substances

  • Antigens, CD
  • Antigens, Differentiation, T-Lymphocyte
  • Biomarkers
  • CD69 antigen
  • Glucocorticoids
  • HLA-DR Antigens
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Interleukin-2 Receptor alpha Subunit
  • Lectins, C-Type
  • Platelet Aggregation Inhibitors
  • Aspirin
  • Methylprednisolone